COMPASS Pathways (CMPS) will not announce any new FDA breakthrough-status update, label expansion, or new regulatory guidance tied to the VA psilocybin news within 90 days.

Predicted 2026-08-15 · Resolves 2026-11-13 · regulatory · USA

72%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

COMPASS Pathways (a company developing its own psilocybin drug, traded on Nasdaq as CMPS) will not announce any new special FDA (the US drug regulator) status, expanded approval, or new regulatory guidance connected to the VA trial news — not by mid-November 2026. The VA runs its own government research program; that process is completely separate from what the FDA does for private companies like COMPASS. Headlines often blur this line, but the two pipelines don't help each other.

Resolution rule: YES if, by 2026-11-13, COMPASS Pathways (Nasdaq: CMPS) has issued NO press release or SEC 8-K/6-K announcing a new FDA breakthrough-therapy update, label expansion, or new FDA guidance explicitly linked to the VA psilocybin program. Checked via COMPASS IR page (ir.compasspathways.com) and SEC EDGAR filings. Resolves NO if any such announcement appears.

Government-run VA trials do not advance a private sponsor's regulatory path. Headlines conflate the two, but the FDA review process for COMP360 is procedurally independent of VA activity. This is anchored to a specific ticker and a falsifiable corporate-disclosure event.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →